Why the study?
Does a 5hmC-derived weighted epigenetic score (eSCORE-CARD) predict composite cardiovascular outcomes in patients with type 2 diabetes?
Population
171 patients with type 2 diabetes, mean age 62.7, 56.7% male, from China. Exclusions: severe heart failure…
Comparison
5hmC-derived weighted epigenetic score based on… vs Low eSCORE-CARD values or T2D patients without AMI
Design
Cohort
Follow-up
median 5.3 years
Key result
A 5hmC-derived weighted epigenetic score (eSCORE-CARD) was significantly associated with an increased risk of composite cardiovascular outcomes (HR 4.25) in patients with type 2 diabetes.
Authors
Loading...
May refine AMI risk stratification in T2D; extends 5hmC epigenetic biomarker research to cardiovascular outcomes.
Cohort (n=171)
No
Does a 5hmC-derived weighted epigenetic score (eSCORE-CARD) predict composite cardiovascular outcomes in patients with type 2 diabetes?
Hazard Ratio: 4.25 (95% CI 1.41–12.8)
p-value: p=<0.05
Yang et al. (2026) conducted a cohort in Type 2 diabetes with or without acute myocardial infarction (n=171). eSCORE-CARD (5hmC-derived weighted epigenetic score) vs. Low eSCORE-CARD score was evaluated on Composite cardiovascular outcomes (CCO) (HR 4.25, 95% CI 1.41-12.80, p=<0.05). A 5hmC-derived weighted epigenetic score (eSCORE-CARD) was significantly associated with an increased risk of composite cardiovascular outcomes (HR 4.25) in patients with type 2 diabetes.